The ICER review is in: hope amidst uncertainty

J Manag Care Spec Pharm. 2022 Jan;28(1):115-118. doi: 10.18553/jmcp.2022.28.1.115.

Abstract

DISCLOSURES: No funding contributed to the writing of this commentary. Smith Begolka, Butler, and Guadalupe are salaried employees of the National Eczema Association, which has received grants and sponsorship awards from a variety of industry partners, including AbbVie, Eli Lilly, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi. Smith Begolka has received grant funding from Pfizer and advisory board honoraria from Pfizer and Incyte. Butler and Guadalupe have received advisory board honoraria from Incyte.

MeSH terms

  • Antibodies, Monoclonal / economics
  • Antibodies, Monoclonal / therapeutic use
  • Cost-Benefit Analysis
  • Dermatitis, Atopic / drug therapy*
  • Drug Costs
  • Humans
  • Janus Kinase Inhibitors / economics
  • Janus Kinase Inhibitors / therapeutic use
  • Medication Adherence
  • Uncertainty*
  • United States

Substances

  • Antibodies, Monoclonal
  • Janus Kinase Inhibitors